Stock Report

All about this stock under one free report Last Updated: 28-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Lasa Supergenerics Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: LASA | BSE: 540702

₹6.97

up-down-arrow ₹0.03 (0.43%)

As on 27-Aug-2026IST

Market cap

info icon

₹35 Cr

Revenue (TTM)

info icon

₹6 Cr

P/E Ratio

info icon

--

P/B Ratio

info icon

0.8

Div. Yield

info icon

0 %

Edit peer-selector-edit
Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 35 35,650 30,141 16,669 15,505
Revenue (₹ Cr)
 6 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 -16.55 1,018.97 497.77 603.02 270.18
Net Margin (%)
 -253.90 10.47 20.72 22.63 23.29
RoE (%)
 -29.40 21.30 28.49 19.61 14.45
Price to Earnings
 -- 35.25 60.55 27.64 56.31
Price-To-Book
 0.77 6.80 14.91 4.78 7.48

Income Statement (₹ Cr)

Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
6.36 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
6.52 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
14.61 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
-8.26 1,943.92 762.90 836.69 388.38
Depreciation arrow
6.01 425.10 98.11 78.88 74.78
EBIT arrow
-14.27 1,518.82 664.79 757.81 313.60
Interest arrow
0.50 148.45 26.33 5.43 0.26
Other Income arrow
0.17 47.39 30.80 73.83 51.50
Exceptional Items arrow
-0.94 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
-15.55 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
1.01 370.94 171.48 197.53 91.39
Profit after Tax arrow
-16.55 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
49.62 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
-0.12 723.57 345.47 142.73 50.51
Current Liabilities arrow
16.77 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
150.87 7,709.37 1,832.56 3,528.05 1,700.71

Assets (₹ Cr)

Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
55.05 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
10.44 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
150.87 7,709.37 1,832.56 3,528.05 1,700.71
Total Debt* arrow
22.08 2,072.49 82.51 0.00 6.23
Net Current Assets arrow
-6.34 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
-- 285.51 27.73 4.82 14.31

Cashflow (₹ Cr)

Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
2.14 1,097.24 261.18 413.52 265.47
Cash Flow from Investing Activities arrow
-0.40 -712.51 -149.69 -116.48 -154.61
Cash from Financing Activities arrow
-1.93 -164.21 -69.28 -279.44 -99.21
Net Cash Inflow / Outflow arrow
-0.19 220.52 42.21 17.59 11.64

Ratios

Profitability Ratios

 Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
-13.23 19.87 33.51 28.31 29.13
ROE (%) arrow
-29.40 21.30 28.49 19.61 14.45
ROA (%) arrow
-19.73 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
-224.58 15.68 28.03 29.25 28.29
Net Margin (%) arrow
-253.90 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
-95.17 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
-100.70 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
50.06 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
-164.28 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
-18.27 18.16 29.06 8.90 18.34

Valuation Ratios

 Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
-2.19 34.53 60.55 26.77 55.81
Price / Book Value arrow
0.77 6.80 14.91 4.78 7.48
Dividend Yield (%) arrow
0.00 0.19 0.14 0.37 0.51
EV/EBITDA arrow
-6.76 18.59 39.30 18.99 38.85
Market Cap (₹ Cr) arrow
110.07 0.00 8,058.80 9,499.31 15,922.01

Solvency Ratios

 Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
-- 0.32 -- -- --
Current Ratio arrow
0.62 1.43 2.09 5.21 7.39
Quick Ratio arrow
0.51 0.82 1.37 3.85 5.46
Interest Coverage arrow
-30.16 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Lasa Supergenerics Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
0.65 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.08 1.09 0.93 0.70 0.52
Receivable days arrow
10.61 94.32 86.10 125.30 111.87
Inventory Days arrow
57.63 78.21 73.73 101.28 75.42
Payable days arrow
56.97 193.72 114.75 149.95 149.88
Cash Conversion Cycle arrow
11.27 -21.19 45.08 76.63 37.41
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...